Active substances
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MYFEMBREE | 1MG;0.5MG;40MG | tablet · oral | SUMITOMO PHARMA AM | Prescription | 26 May 2021 |
Ryeqo is indicated in adult women of reproductive age for: treatment of moderate to severe symptoms of uterine fibroids, symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MYFEMBREE | 02541742 | 40 MG; 1 MG; 0.5 MG | TABLET · ORAL | KNIGHT THERAPEUTICS INC. |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | MYFEMBREE 40 MG-1 MG-0.5 MG TB | $45.25137 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.